Concerns, Catalysts & Risks -- 7/10
Zero China exposure; trades roughly in line with CME/ICE/Nasdaq on forward P/E (~20.5x) and at
a real ~20% discount on EV/EBITDA (~14.2x vs. ~17.8x peer average), consistent with its
net-cash balance sheet. Four concrete catalysts in motion. Held below the top of the range by
a real, management-acknowledged SEC/CFTC jurisdictional overhang on event contracts, plus a
longer-dated competitive question about the SPX license's ~2032 exclusivity horizon.
Weight: 15%
Forward P/E
20.5x
In line with peer avg ~20.6x
EV / EBITDA
~14.2x
~20% discount to peer avg ~17.8x
China Exposure
~0%
No China-domiciled business
Active Catalysts
4
Mostly ahead, not behind, the P&L
Valuation table
| Metric | FY+1 (FY2026) Estimate | Multiple (Current Price) | Peer Avg (CME/ICE/NDAQ) |
|---|---|---|---|
| P/E | EPS $13.77 (consensus avg) | 20.5x | ~20.6x (CME ~20-22x, ICE ~18.8x, NDAQ ~21.8x) |
| EV / EBITDA | Adj. EBITDA ~$2.05B (guidance-anchored, see note) | ~14.2x | ~17.8x (CME ~18.8x, ICE ~15.9x, NDAQ ~18.7x) |
Data-quality note: FMP's
analyst-estimates endpoint reports
FY2026 EBITDA consensus of only $827.2M on $2.83B revenue (~29% margin) -- inconsistent with
Cboe's own reported margin framework (FY2025 Adjusted EBITDA $1,645.5M on $2,429.1M net
revenue = 67.7% margin). Rather than propagate a stale/mis-mapped FMP field, the EV/EBITDA
line is reconstructed off Cboe's own FY2026 guidance (consensus revenue less guided adjusted
opex/D&A midpoints ≈ $2.05B adjusted EBITDA). P/E is unaffected -- FMP's consensus EPS
($13.77) is consistent with the company's own adjusted-diluted-EPS basis. Peer figures are
web-sourced current forward multiples (July 2026), directional not exact-vintage-matched.
Source: FMP
/stable/ratios, /stable/key-metrics, /stable/analyst-estimates, /stable/quote. Read: Cboe trades roughly in line with peers on P/E and at a meaningful discount on EV/EBITDA, consistent with its net-cash balance sheet.China exposure
Not disclosed as a reporting line and not material -- effectively 0%. No
China-domiciled exchange or listing business; only history is a decade-old (2005)
non-binding information-sharing MOU. International footprint is narrowing further
post-realignment (Japan exited, Australia/Canada sale agreed) toward a North America/Europe
core.
Catalysts
| # | Catalyst | Detail |
|---|---|---|
| 1 | Event/prediction market launch | Mini-SPX vertical-spread binary contracts, "subject to regulatory approval" per Q1 2026 call -- targeting a Q2 2026 launch, explicitly contingent on the regulatory question below. |
| 2 | Australia/Canada sale closing | Definitive agreement reached; $40M-$50M annualized savings not yet in 2026 guidance, timing subject to separate regulatory approvals in each jurisdiction. |
| 3 | FedEx (European derivatives) wind-down | Confirmed complete/completing, embedded in 2026 expense guidance. |
| 4 | Realignment savings realization | $100M-$120M aggregate target; only $20M-$25M of the newest actions in 2026 guidance -- remainder a multi-quarter tailwind still mostly ahead. |
Regulatory / political risk
The most significant unresolved overhang
Verbatim Q1 2026 transcript, CEO Donohue in response to a direct question on SEC/CFTC
jurisdiction over index-linked event contracts: "It is clear that binary options that
are based on a broad-based stock index are a securities-based product. That's an ongoing
conversation that we're having, and I think we're very hopeful and optimistic that
regulatory clarity ultimately will result in no impact to our licensed products."
"Hopeful and optimistic" is not resolved. A second, longer-dated risk raised the same
call: analysts asking directly about "other exchanges looking to compete for the SPX
contract in 2032" -- management's defense is ecosystem depth (34 broker platforms,
11 floor-broker groups, 20 market-making groups), not a structural moat guarantee.
Bull case / bear case
Bull Case
Record, accelerating results across all five segments with margins expanding every
quarter; net-cash balance sheet funding buybacks/dividends while investing in event
contracts, clearing, and tokenization; a self-inflicted realignment that both raises
growth-algorithm quality and banks $100M-$120M of savings still mostly ahead of the
P&L; a genuine first-mover position in exchange-native, securities-regulated event
contracts if the SEC/CFTC question resolves favorably. Valuation supports this:
EV/EBITDA at a ~20% discount to peers despite superior growth/margin trajectory.
Bear Case
The realignment reads as tacit admission that a decade of acquisitions (workforce
roughly doubled since 2020) diluted focus. The 2026 guidance raise is "largely
reflecting the incremental realignment savings, not just underlying demand" -- some of
the Street-cheered "acceleration" is a cost-cut optical effect. The event-contract
growth engine and the SPX royalty franchise both sit on regulatory/contractual
foundations Cboe does not fully control, and management's own language concedes the
outcome isn't guaranteed. Execution risk on two more cross-border divestitures remains
open pending separate regulatory approvals.
Assessment
CBOE screens well but not perfectly: China exposure is a non-issue, valuation is in line to at-a-discount vs. peers, and four concrete, largely self-funded catalysts are in motion. What keeps this off the top of the scale is a real, management-acknowledged regulatory overhang (SEC/CFTC jurisdiction on event contracts, explicitly unresolved) layered on a longer-dated competitive question about SPX exclusivity that the Street is already pricing in six years ahead of expiry. Score: 7/10.
Data sourced from Daloopa, FMP (
/stable/ratios, /stable/key-metrics, /stable/analyst-estimates, /stable/quote), verbatim FMP earnings-call transcripts, and web search (peer multiples). Full detail: tickers/CBOE/data/review_workspaces/2026-07-24/final_score.md.